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Background: Nonsense mediated mRNA decay (NMD) is an RNA surveillance mechanism that controls RNA
stability and ensures the speedy degradation of erroneous and unnecessary transcripts. This mechanism depends
on several core factors in the exon junction complex (EJC), eIF4A3, RBM8a, Magoh, and BTZ, as well as peripheral
factors to distinguish premature stop codons (PTCs) from normal stop codons in transcripts. Recently, emerging
evidence has indicated that NMD factors are associated with neurodevelopmental disorders such as autism
spectrum disorder (ASD) and intellectual disability (ID). However, the mechanism in which these factors control
embryonic brain development is not clear.
Result: We found that RBM8a is critical for proliferation and differentiation in cortical neural progenitor cells (NPCs).
RBM8a is highly expressed in the subventricular zone (SVZ) of the early embryonic cortex, suggesting that RBM8a may
play a role in regulating NPCs. RBM8a overexpression stimulates embryonic NPC proliferation and suppresses neuronal
differentiation. Conversely, knockdown of RBM8a in the neocortex reduces NPC proliferation and promotes premature
neuronal differentiation. Moreover, overexpression of RBM8a suppresses cell cycle exit and keeps cortical NPCs in a
proliferative state. To uncover the underlying mechanisms of this phenotype, genome-wide RNAseq was used to identify
potential downstream genes of RBM8a in the brain, which have been implicated in autism and neurodevelopmental
disorders. Interestingly, autism and schizophrenia risk genes are highly represented in downstream transcripts of RBM8a.
In addition, RBM8a regulates multiple alternative splicing genes and NMD targets that are implicated in ASD. Taken
together, this data suggests a novel role of RBM8a in the regulation of neurodevelopment.
Conclusions: Our studies provide some insight into causes of mental illnesses and will facilitate the development of new
therapeutic strategies for neurodevelopmental illnesses.
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Autism spectrum disorder (ASD) is a neurodevelopmen-
tal disorder characterized by impaired social and com-
munication skills, repetitive, stereotyped behaviors, and
often intellectual and cognitive impairments. Intellectual
disability (ID) affects roughly 2–3 % of people worldwide* Correspondence: yzm1@psu.edu
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creativecommons.org/publicdomain/zero/1.0/[1], and is commonly found in autistic patients. ID typic-
ally manifests with an early onset of cognitive impair-
ment. According to The Diagnostic and Statistical
Manual of Mental Disorders V (DSM-V), ID is defined
by significant deficits in three areas of adaptive behaviors
(i.e. conceptual skills, self-help skills, interpersonal skills).
Patients with ID normally have the IQ score approximately
two standard deviation below the general population, i.e.
IQ < 70. Children with ID learn more slowly than a normal
child in terms of language, social skills, and the ability to
take care of personal needs, such as dressing and eating.le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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always noticeable during the first years of life.
Recently, mutations in a factor involved in nonsense-
mediated mRNA decay (NMD), Upf3b, have been found
in patients with X-linked ID, autism and early onset
schizophrenia [1–3], suggesting an important role for
NMD in regulation of neuronal gene expression and
mental health. Increasing evidence shows that mutations
in NMD factors contribute to neurodevelopmental dis-
orders. In particular, a core exon junction complex (EJC)
factor, RBM8a (located in the 1q21.1 chromosome re-
gion) is associated with ID, ASD [4], schizophrenia
(SCZ) [5], and microcephaly [6]. Duplication of the 1q21.1
region is strongly associated with autism [6]. Moreover,
RBM8a loss-of-function causes thrombocytopenia-absent-
radius (TAR) syndrome [7] which is often comorbid with
ID [8]. Other brain dysfunctions, including psychosis,
agenesis of the corpus callosum, and hypoplasia of the
cerebellar vermis, are present in TAR patients [8, 9].
In addition, rare mutations on Upf1 have been found
in patients with ASD and SCZ [10]. Recently, a muta-
tion in eIF4A3 gene leads to Richieri-Costa-Pereira
syndrome with learning disability [11].
NMD was originally identified as an RNA surveillance
mechanism that degrades mRNAs possessing a prema-
ture termination codon (PTC). The EJC, which consists
of four core proteins (eIF4AIII, BTZ, MAGOH, and
RBM8a), is essential for NMD [12]. The EJC core serves
as a platform to recruit other peripheral proteins, such
as Upf1/2/3X [13] and SMG1/5/6/7 [14], to form the
SURF complex [15], which breaks down mutated tran-
scripts before translation [13, 14, 16]. Intriguingly, besides
RNA surveillance, NMD also regulates the abundance of
normal mRNAs [17–19]. Alternative branches of NMD
have been discovered [20–22], arguing that different
NMD factors may control distinct groups of transcripts
instead of the same pool of mRNAs, thereby modulating
unique functions [23–32]. To support this notion, several
studies have revealed common and unique transcripts reg-
ulated by several NMD factors [33–38]. These findings
support the hypothesis that NMD plays an important role
in the control of gene expression involving a variety of
biological processes [23, 24, 26–31, 34, 39–41].
There has also been increasing evidence that NMD
proteins play a role in neurodevelopment. Magoh hap-
loinsufficiency was found to cause microcephaly in mice,
in addition to disorganized cortical layers, ectopic differ-
entiation, and mitotic spindle defects [30, 42]. Upf3b has
also been found to play a role in neurodevelopment.
Loss of function of Upf3b leads to an increased number
of NPCs, paired with a decrease in differentiation. Upf3b
is also instrumental in neural maturation, as loss of
Upf3b results in subtle neurite outgrowth defects [43].
Further evidence supporting the notion that NMDproteins are involved in development is a study con-
ducted on Upf1, and its role in proliferation and differ-
entiation. Upf1 was found to promote the stem like state
of cells, and is downregulated to promote differentiation.
Specifically, Upf1 promotes proliferation at the transition
from G1 of the cell cycle to the S phase. These changes
were found to be mediated by the TGF-β pathway
[35]. Additionally, studies in Drosophila melanogaster have
shown that loss of mago (homologue of Magoh), prevents
EGF signaling via downregulation of the MAPK pathway.
This modulation of the MAPK pathway is dependent of
EJC factors, Mago, RBM8a, and eIF4AIII. The reduction of
MAPK signaling is due to alternative splicing of MAPK,
while transcriptional levels and RNA stability of MAPK is
maintained [40, 41]. The EJC’s regulation of alternative
splicing is not just specific to MAPK, but also includes
other long, intron containing genes [40, 41].
RBM8a, an EJC factor, is a ribonucleoprotein with an
RNA binding motif that preferably binds to mRNAs dur-
ing splicing [44]. Its role in NMD has been extensively
studied [45, 46]. However, specific cellular functions me-
diated by RBM8a have not been well characterized. In
addition to controlling mRNA stability, RBM8a also
regulates mRNA splicing [47, 48] and translation [49].
RBM8a was found in an mRNA export machinery
through importin13 [44]. Localization of some specific
mRNAs in Drosophila melanogaster determines its em-
bryonic polarity. RBM8a and other EJC factors anchor
Oskar mRNA at the posterior pole of the oocyte and
regulates Oskar localization, and thereby control oocyte
maturation [50, 51]. In addition, RBM8a associates with
the C-terminal domain of Stat3 and regulates Stat3 tran-
scriptional activity through modulation of tyrosine phos-
phorylation [52]. As these studies used special cell types,
it is still unclear whether these RBM8a-mediated func-
tions can be observed in other cell types.
Despite the genetic studies strongly implicating that
NMD is crucial for neural functions [53], very little is
known about its specific effects on the neural development.
To determine the role of NMD in the central nervous sys-
tem, we first examined the function of RBM8a in the em-
bryonic NPC. Our data supports a positive role of RBM8a
in regulating NPC proliferation. Loss-of-function of RBM8a
leads to abnormal NPC proliferation and differentiation. To
determine the underlying mechanism, an unbiased RNAseq
of the transcriptome of SY5Y cells overexpressing RBM8a,
has revealed multiple important functions regulated by
RBM8a that have not been previously reported.
Results
RBM8a is highly expressed in neural progenitors during
brain development
To test the role of RBM8a in brain development, we first
examined its expression in mouse brains from E9 to
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cantly higher level of RBM8a when NPCs are actively
proliferating (E10-E13), and then have decreased expres-
sion at E14 when NPCs begin to differentiate (Fig. 1a).
Interestingly, the NPC marker, Sox2, exhibits a similar
expression pattern, suggesting that RBM8a may share
similar functions as Sox2. We next tested whether
RBM8a expression changed during primary NPC differ-
entiation. NPCs were isolated from E14 mouse brains
and then induced to differentiate for 7 days in vitro.
RBM8a levels were dramatically reduced after differenti-
ation (Fig. 1b). In the embryonic cerebral cortex, RBM8a
is robustly expressed in nestin positive neural progeni-
tors residing in the ventricular zone (VZ)/subventricular
zone (SVZ) (Fig. 1c), but reduced in doublecortin (DCX)
positive progenitors or immature neurons in the inter-
mediate zone (IZ) and the cortical plate (CP) (Fig. 1d).
The striking expression pattern of RBM8a suggest that it
may play an important role in progenitor proliferation
and differentiation.
RBM8a promotes neural progenitor cell proliferation
As NMD has been implicated in cell proliferation [54, 55],
we generated two short hairpin RNAs (shRNAs) against
the endogenous mouse RBM8a gene. The two shRNAsFig. 1 RBM8a expression in embryonic brain. a Expression of RBM8a in em
but reduced in differentiated neurons. c Co-immunostaining of RBM8a (red
Co-immunostaining of RBM8a (red) and DCX (green) in E16 embryonic cor
in the VZ/SVZ, but low in the IZ and the CP. CP, cortical plate; IZ, intermedspecifically knocked down RBM8a in CAD cells, a well-
established mouse neuroblastoma cell line, which can pro-
liferate and differentiate (Additional file 1A). The specificity
of RBM8a staining was verified using CAD cells transfected
with either control or RBM8a shRNA (Additional file 1B),
in which CAD cells expressing RBM8a shRNA (GFP
positive) showed lower RBM8a staining compared to
the GFP-negative cells in the same field. Based on its
expression in neural progenitors, we next looked into a
potential role for RBM8a in cell proliferation in vitro.
When RBM8a was knocked down in CAD cells, BrdU
labeling (0.5 h pulse) and mitotic index were dramatic-
ally decreased by more than 3-fold (Additional file 2A
and B). As duplication of 1q21 region has also been im-
plicated in neurodevelopmental disorders, the reduced
proliferation by RBM8a knockdown encouraged us to
pursue the reciprocal RBM8a gain-of-function experi-
ment. Remarkably, overexpression of full length human
RBM8a stimulates a 2-fold increase in cell proliferation,
2-fold increase in both BrdU incorporation and mitotic
index (Additional file 2C and 2D). Thus, RBM8a is re-
quired for the normal proliferation and its overexpres-
sion promotes proliferation.
We next tested how change of RBM8a expression af-
fects NPC behaviors in vivo. In utero electroporationbryonic brain from E9 to adult. b RBM8a is highly expressed in NPCs
) and Nestin (green) in E16 embryonic cortex. Scale bar = 20 μm. d
tex. Scale = 20 μm. Noticeably, Nestin + NPCs express high RBM8a level
iate zone; VZ/SVZ, ventricular zone/subventricular zone
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mouse brains (Fig. 2a). RBM8a shRNA and a GFP plas-
mid were co-delivered into neural progenitors by injec-
tion into the ventricle, and application of an electrical
current was then used to direct the plasmid DNA into
specific populations of progenitor cells. As neural pro-
genitor cells divide and differentiate, newborn neurons
migrate from the VZ/SVZ through the IZ and into the
developing CP to their final destination where they exist
fully mature. We therefore tested the effect of RBM8a
on NPC position and proliferation at E16, which is a
time of peak neurogenesis. Knockdown of RBM8a from
E13 to E16 in utero decreased the cell number at the
VZ/SVZ, and increased the number of cells migrating
into the CP, where differentiated neurons are localized
(Fig. 2a). To confirm the migration defect caused by
RBM8a knockdown, we electroporated RBM8a shRNA2
at E15, when neuronal migration peaks (Additional file
3A). After harvesting brains at E18, similar migration
defects were observed. Conversely, RBM8a overexpres-
sion led to a decrease in the cell number migrating into
the CP (Fig. 2b), suggesting that RBM8a up-regulationFig. 2 RBM8a regulates cell position in the cortex. a Confocal images of E1
of shRNA constructs at E13. The graph shows that knockdown of RBM8a si
and increased the cell number in the CP. *, p < 0.05. **, p < 0.01; n = 3-4, t-t
in utero electroporation of an overexpression construct at E14. Quantificatio
number of GFP-positive cells in the CP. *, p < 0.05. **, p < 0.01; n = 3-4, t-tesmay impair the NPC development process. These results
suggest that NPC proliferation is reduced and neuronal
differentiation is increased after RBM8a knockdown,
whereas RBM8a overexpression suppresses neuronal
differentiation.
We hypothesize that RBM8a may regulate cell posi-
tioning by affecting NPC proliferation in utero. To test
this hypothesis, we first knocked down RBM8a at E13
and pulse-labeled embryos with BrdU (10 mg/kg) to
label progenitors undergoing DNA replication 2 h prior
to collection of the electroporated brains. The E16
brains were subsequently harvested. Staining for BrdU
revealed that knockdown of RBM8a significantly de-
creased the percentage of double positive cells for GFP/
BrdU (Fig. 3a), supporting the postulate that RBM8a
knockdown expression reduces the number of proliferat-
ing NPCs. Consistently, the active cell cycle marker,
Ki67, is decreased in the RBM8a knockdown cells
(Fig. 3b). Conversely, when RBM8a was overexpressed at
E14, we detected an increase of GFP/BrdU double-
positive cells (Fig. 4a) at E16. Interestingly, RBM8a over-
expression promotes cell division, as more GFP positive6 brain sections showing cell positioning after in utero electroporation
gnificantly decreased the number of GFP-positive cells in the VZ/SVZ
est. Scale bar = 20 μm. b E16 brain sections show cell positioning after
n shows that overexpression of WT-RBM8a significantly decreased the
t. Scale bar = 20 μm
Fig. 3 RBM8a knockdown decreases NPC proliferation. a RBM8a was knocked down at E13, and pulse labeled with BrdU (100 mg/kg) for 2 h. E16
brain sections were stained for BrdU (red) and GFP (green). Arrowheads indicate GFP-BrdU double-positive cells. Graphs show the percentage of
GFP/BrdU double positive cells in each condition. *, p < 0.05; n = 4. t-test. Scale bar =10 μm. b E16 brain sections were stained for Ki67 (red) and
GFP (green). Arrowheads indicate GFP-Ki67 double-positive cells. Graphs show the percentage of GFP/Ki67 double positive cells in each condition. *,
p < 0.05; n = 4.t-test. Scale bar =10 μm
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than from vector control (Fig. 4b). These data suggest
that RBM8a is a positive regulator for NPC proliferation.
RBM8a modulates cell cycle progression and neuronal
differentiation
Our data suggest the cell cycle may be changed by
RBM8a silencing. To test this possibility, we examined
the cell cycle exit index. RBM8a shRNA constructs were
electroporated into E13 mouse brains and BrdU was
injected into pregnant dams 2 days later, at E15. Sections
from E16 brains were collected and stained using
anti-GFP, −BrdU, and -Ki67 antibodies (Fig. 5a).
GFP+/BrdU+/Ki67+ cells (arrows) were in S phase at
E15 and remain cycling at E16 (Fig. 5a). GFP+/
BrdU+/Ki67- cells were in S phase at E15, but exited
the cell cycle by E16 (arrowheads). The cell cycle
exit index represents the ratio of GFP+/BrdU+/Ki67- to
total GFP+/BrdU+ cells. We observed a 32 % increase in
cell cycle index in RBM8a shRNA transfected embryonic
brains, suggesting that the reduction of proliferating pro-
genitors in RBM8a shRNA treated brains probably results
from increased cell cycle exit. To further evaluate the fate
of the cells that exited the cell cycle, we immunostained the
brain sections for β-III tubulin (Tuj1), a marker for newlygenerated neurons (Fig. 5b). A significant increase in Tuj1
positive cells was observed with RBM8a shRNA transfected
cells (76 ± 2.4 % for shRNA-2) compared to control shRNA
transfected cells (54.5 ± 1.7 %) (Fig. 5b, Additional file 3B).
Taken together, these results suggest that loss of RBM8a ex-
pression causes premature neuronal differentiation at the
expense of the progenitor pool.
As upregulation of RBM8a increases NPC proliferation,
we hypothesize that RBM8a overexpression suppresses the
cell cycle exit thereby increasing proliferation. Consistently,
we observed about 30 % decrease of cell cycle exit when
RBM8a level is upregulated (Fig. 6a). To further examine
neuronal differentiation of NPCs when RBM8a is overex-
pressed, brain sections were co-stained with Tuj1 and
GFP antibodies. Consistent with increased proliferation of
NPCs, upregulation of RBM8a significantly suppresses
neuronal differentiation (Fig. 6b, Additional file 3C). To-
gether, these data suggest that an optimal level of RBM8a
is essential for proper cell cycle control and NPC differen-
tiation (Figs. 5 and 6).
Genes regulated by RBM8a
Our results have shown that altered expression of RBM8a
impedes NPC proliferation (Figs. 3 and 4) and impairs
neuronal differentiation (Figs. 5 and 6). Although several
Fig. 4 RBM8a overexpression increases NPC proliferation. a RBM8a was overexpressed at E14, and E16 brain sections were stained for BrdU (red)
and GFP (green). Arrowheads indicate GFP-BrdU double-positive cells. Graphs show the percentage of GFP/BrdU double positive cells in each
condition. *, p < 0.05; n = 3–4. t-test. Scale bar = 10 μm. b E16 brain sections were stained for Ki67 (red) and GFP (green). Arrowheads indicate
GFP-Ki67 double-positive cells. Graphs show the percentage of GFP/Ki67 double positive cells in each condition. **, p < 0.01; n = 3–4. t-test.
Scale bar = 10 μm
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neural tissues [50, 51, 56], it is unknown what molecular
targets and signaling pathways are regulated by RBM8a. To
identify differential expressing genes regulated by RBM8a,
we have established a stable neural SH-SY5Y cell line over-
expressing RBM8a in vitro (Additional file 4A). The RNA-
Seq platform is capable of identifying relative expression,
alternative splicing, novel transcripts and isoforms, RNA
editing, and allele-specific expression. RNAs from control
and induced cells, in which rRNAs have been removed,
were sequenced using the Illumina HiSeq 2500 system. Un-
biased RNASeq generates 50 million high-quality paired-
reads per sample (at 50 nt) (Additional file 4B and C) and
over 95 % of the reads are mapped back to the reference
genome. We have found that 7.08 % of transcripts are dif-
ferentially expressed when RBM8a is overexpressed, which
is consistent with other studies [17–19, 57]. Interestingly,
the most affected transcripts are protein coding mRNAs
(94.7 %) and the others are noncoding RNAs. The three lar-
gest groups of noncoding RNAs include lincRNAs (1.57 %),
antisense RNAs (1.17 %), and pseudogenes (1.46 %) (Fig. 7a,
Additional file 5: Table S1). These genes represent down-
stream factors that mediate RBM8a functions.
First, we compared RBM8a-regulated genes with exist-
ing databases for psychiatric risk genes to determine
whether there were significant gene overlaps. Using thehypergeometric analysis we determined that risk genes
in ID, Alzheimer’s disease (AD) [58], ASD [59, 60] and
SCZ [61–63] but not Crohn’s disease [64], are over-
represented in RBM8a downstream gene targets (Fig. 7b,
Additional file 6: Table S2), suggesting that genes com-
mon in both datasets are not likely due to by chance. To
examine the protein level of the RNAseq results in
mouse CAD cells, we tested genes involved in autism
risk (NLGN1) [65], neurodegeneration (ATXN1) [66],
neurogenesis (REST) [67], embryonic development (TLE4)
[68], and neuronal migration (KIF1A) [69]. Consistent with
the RNA levels from our RNAseq data (Fig. 7c), overex-
pression of RBM8a in CAD cells also produces corre-
sponding level of proteins (Fig. 7d). In the other hand,
knockdown of RBN8a generates reversal level of proteins
of these genes in CAD cells (Fig. 7e). Therefore, these re-
sults confirm the validity of our RNAseq data and support
the theory that RBM8a is involved in increased risk for
mental illnesses.
To analyze the underlying signaling pathways that are
regulated by RBM8a, we utilized the DAVID Bioinfor-
matics tool [70]. Based on our dataset of RBM8a regu-
lated genes, DAVID determined that RBM8a regulates
genes involved in several processes vital for embryonic
brain development (Fig. 8a), including the MAPK path-
way (Fig. 8b), growth factor signaling (Fig. 8c), the Rho
Fig. 5 RBM8a knockdown in NPCs causes premature cell cycle exit and neuronal differentiation in utero. a Control or RBM8a shRNA constructs
were electroporated into E13 embryonic brains and BrdU was injected at E15. Mice were sacrificed at E16. The cell cycle exit index is calculated
as the percentage of the GFP-positive cells that exited the cell cycle (GFP+ BrdU+ Ki67-) divided by total GFP and BrdU double positive (GFP+
BrdU+) cells. n= 3-4, *, p< 0.05, t-test. Scale bar = 10 μm. White arrows indicate GFP + BrdU+ Ki67+ cells. Arrowheads indicate GFP + BrdU + Ki67- cells.
b Control or RBM8a shRNA constructs were electroporated into E13 embryonic brains and mice were sacrificed at E16. E16 brain section were stained with
neuronal marker Tuj1 (red) and GFP (green). Graphs show the percentage of GFP/Tuj1 double positive cells in each condition. **, p< 0.01; n= 3–4. t-test.
Scale bar = 10 μm
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including integrins and collagens (Fig. 8E), and Ca2+ sig-
naling (Fig. 8f ). Our data demonstrates that RBM8a
regulates many functions during brain development
(Fig. 8, Additional file 7: Table S3). Intriguingly, besides
genes that are required for neurodevelopment, our data
also indicates that RBM8a regulates genes involved in
kidney, urogenital system and vasculature development
(Additional file 7: Table S3). This is consistent with the
fact that TAR patients often develop renal and cardio-
vascular anomalies [71].
Next, since EJC proteins have been implicated in alter-
native splicing [72], we investigated whether RBM8a
overexpression leads to change of differential alternative
splicing. Our dataset identified that 371 alternative splicing
events in 101 protein coding genes were significantly al-
tered (Fig. 9a, Additional file 8: Table S4). In contrast to
hnRNP A1 [73], an alternative splicing regulator, RBM8a
overexpression gives rise to fewer alternative splicingevents, indicating that while RBM8a does have an effect on
alternative splicing, it is not an a global splicing regulator.
Interestingly, the alternatively spliced protein coding genes
are significantly enriched in ASD risk genes (Additional
file 9: Table S5). Interestingly, these genes regulates small
GTPase activity, PPAR binding and cell morphogenesis
(Fig. 9b).
As RBM8a is involved in NMD, we wanted to ascer-
tain whether or not our differentially expressed RNAs
are NMD targets. Characteristics of RNAs targeted by
NMD are long 3′ UTRs (greater than 1250 bp), an in-
tron in the 3′UTR, or an exon junction >50 nt down-
stream of a stop codon [74]. We assessed our list of
differentially expressed RNAs to determine how many
exhibit characteristics that would make the RNA prone
to degradation via NMD. 814 genes out of 1788 differen-
tially expressed genes were determined to possess fea-
tures that make the RNA susceptible to NMD (Fig. 9c,
Additional file 10: Table S6). We were also interested in
Fig. 6 RBM8a overexpression prevents cell cycle exit and neuronal differentiation in utero. a Control or RBM8a overexpressing constructs were
electroporated into E14 embryonic brains and BrdU was injected at E15. Mice were sacrificed at E16. The cell cycle exit index is calculated as the
percentage of the GFP-positive cells that exited the cell cycle (GFP+ BrdU+ Ki67-) divided by total GFP and BrdU double positive (GFP+ BrdU+)
cells. n = 3-4, *, p < 0.05, t-test. Scale bar = 10 μm. White arrows indicate GFP + BrdU + Ki67+ cells. Arrowheads indicate GFP + BrdU + Ki67- cells.
b Control or RBM8a overexpressing constructs were electroporated into E14 embryonic brains and mice were sacrificed at E16. E16 brain section
were stained with neuronal marker Tuj1 (red) and GFP (green). Graphs show the percentage of GFP/Tuj1 double positive cells in each condition. ***,
p < 0.001; n = 3–4. t-test. Scale bar = 10 μm
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expressed RNAs targeted by NMD. We found that this
subset of RNAs regulates many processes associated
with neural development (Fig. 9d). Seeing as we previ-
ously determined that our differentially expressed RNAs
were enriched for neurological disease risk gene, we
tested if this phenomenon held true for those RNAs tar-
geted by NMD. In fact, we did see that our dataset was
enriched with risk genes for ASD, SCZ, AD, and ID, but
not Crohn’s disease (Additional file 11 and Additional
file 12: Table S7). Interestingly, among the 97 genes that
are involved in ASD risks, many modulate neurodeve-
lopment and synaptic function (Additional file 11B).
Discussion
During early brain development, NPCs in the SVZ/VZ
can self-renew and differentiate into neurons. The devel-
opment of the nervous system is a delicate balance of
proliferation and differentiation. Enough NPCs need to
remain NPCs to give rise to a sufficient number of cells
to support the organism, while some NPCs need to dif-
ferentiate in order to build the nervous system, so the
organism can support itself. In this study, we demon-
strated that RBM8a plays a key role in NPC proliferation
and differentiation. First, RBM8a is highly expressed inthe SVZ of early embryonic cortex. To confirm the role
of RBM8a in early neurogenesis, in utero electroporation
using RBM8a shRNA in mouse embryonic brains has
demonstrated that knockdown of RBM8a leads to de-
creased number of cells in the VZ/SVZ, and more cells
in the CP (Fig. 2a). This suggests that fewer NPCs are
remaining as NPCs, and more NPCs are differentiating
and migrating to the CP. Conversely, when RBM8a is
overexpressed, more NPCs are remaining in the VZ/SVZ
and proliferating, while less cells are present in the CP,
suggesting that fewer cells are differentiating and migrat-
ing to the CP (Fig. 2b). Moreover, overexpression of
RBM8a suppresses cell cycle exit and keeps cortical
NPCs in proliferative state. The loss and gain of function
data indicate that RBM8a promotes proliferation, while
suppressing differentiation. Therefore, we conclude that
RBM8a stimulates embryonic NPC proliferation and sup-
presses neuronal differentiation, indicating that RBM8a
positively regulates NPC proliferation.
NMD factors are known to control embryogenesis.
Upf2 is involved in development of hematopoietic stem
cells [75]. The first study of Magoh mutant mice demon-
strated the important role of EJC in NPC division [30].
Recently, Upf1 has been shown to be sufficient to pro-
mote neural differentiation and inhibit NPC proliferation
Fig. 7 Illumina RNAseq from RBM8a over-expression. a RNA types that are changed by RBM8a. b Downstream genes regulated by RBM8a were
cross referenced with different diseases including AD, ASD, ID, SCZ and Crohn’s diseases. c Fold change of RNA level of NLGN1, ATXN1, REST,
TLE4, KIF1A from RNAseq. d Protein level of NLGN1, ATXN1, REST, TLE4, KIF1A in CAD cells overexpressing RBM8a. Bar graph shows the fold
change of protein level normalized to vector expressing cells. e Protein level of NLGN1, ATXN1, REST, TLE4, KIF1A in CAD cells silencing RBM8a.
Bar graph shows the fold change of protein level normalized to control shRNA expressing cells
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RBM8a participates in the NMD pathway and controls
mRNA splicing and degradation [15, 76, 77], the role of
RBM8a in the embryonic brain is unclear. Our data
strongly supports a vital role of RBM8a in the mainten-
ance of a NPC pool in the VZ/SVZ. The first evidence is
that the expression of RBM8a is high in the Nestin-
positive progenitors of the developing cortex (Fig. 1c).
Second, RBM8a expression level is decreased when
NPCs differentiate into neurons in the CP (Fig. 1),
suggesting the expression level of RBM8a critically
determine the stemness of NPCs. Consistent with this
notion, knockdown of RBM8a significantly decreases
NPC proliferation and promotes neuronal differentiation
(Figs. 3 and 5). Additionally, RBM8a controls the cell
cycle of NPCs. Thus, our data is consistent with recent
studies that the NMD activity is important in maintain-
ing the balance of proliferation and differentiation in
NPCs [30, 35, 55].
Our knockdown data is consistent with a recently pub-
lished paper that illustrated that RBM8a haploinsufficiency
causes ectopic neuronal differentiation, and disrupts the
balance between proliferation and differentiation [78].However, our data suggests that RBM8a overexpression tips
the balance between proliferation and differentiation in the
opposite direction as RBM8a knockdown, which they did
not detect. This difference may most likely be attributed to
the promoter used to drive RBM8a expression. Different
promoters can lead to a different level of RBM8a expres-
sion, which might explain the variation of phenotype.
Several mechanisms may underlie the loss-of-function
phenotypes of NMD in NPCs. Magoh regulates mitosis
of NPCs through LIS1 [30]. To uncover the underlying
mechanisms regulated by RBM8a, genome-wide RNAseq
identifies potential substrates of RBM8a in the brain,
which have been implicated in neurogenesis and plasti-
city. However, our RNA-seq analysis has indicated that
Lis1 is not differentially expressed when RBM8a is over-
expressed, suggesting that Lis1 might not be a down-
stream target of RBM8a. Although Magoh and RBM8a
form a heterodimer in conjunction with their role in
NMD, increasing evidence has illustrated that the two
proteins may have differential roles in aspects independ-
ent of NMD. In humans, TAR syndrome occurs when
there is a compound mutation in RBM8a (deletion of
the 1q.21.1 region in one allele, and a mutation in the
Fig. 8 Pathway analysis of genes that are modulated by RBM8a. a Major functions regulated by RBM8a. b The fold changes of factors in the
MAPK pathway. Graphs show the fold changes of mRNA expression over control. c The fold changes of genes in growth factors. d The fold
changes of factors in the Rho pathway e ECMs are regulated by RBM8a. f The fold changes of factors in the calcium signaling
Fig. 9 RNAseq analysis of alternative splicing and NMD targets. a The percentage of each alternative splicing type found in the dataset, skipped
exon (SE), alternative 3′ splice site (A3SS), alternative 5′ splice site (A5SS), alternative last exon (ALE) and alternative first exon (AFE). b Functions
mediated by alternatively spliced genes. c The percentage of differentially expressed RNAs that possess characteristics making it prone to
degradation via NMD. d Functional clusters based on differentially expressed RNAs that are prone to NMD
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ever, does not seem to involve Magoh. Genetically this
disorder is attributed to mutations in the RBM8a gene,
but not Magoh. Additionally, it has been shown that
RBM8a shuttles between the nucleoplasm and cytoplasm
independent of Magoh, further supporting the theory
that RBM8a and Magoh have independent functions, in
addition to their role in NMD [79]. RBM8a is also
known to positively regulate TNF-α induced IL-6 ex-
pression in HeLa cells, which Magoh is not involved in
[80]. Together, these studies suggest that RBM8a and
Magoh each have separate functions from each other, in
addition to their collaborative role in NMD.
RBM8a may play a regulatory role in several stages
during brain development. Our data indicates that alter-
ation of RBM8a expression impairs neuronal migration
(Fig. 2). ECM proteins including integrin and collagens
are crucial for neurogenesis [81]. ECMs are differentially
expressed when RBM8a is overexpressed (Fig. 8e),
suggesting that RBM8a regulates neuronal migration
through ECM proteins. Previously it has been shown
that alteration of RBM8a level in the adult dentate gyrus
affects anxious behaviors in mice [55]. Consistently, we
have found that RBM8a overexpression significantly af-
fects genes involved in calcium signaling, which is re-
quired for neurotransmission. This change in calcium
signaling may explain the abnormal behaviors seen in
mice who have increased RBM8a expression in the den-
tate gyrus. This sequencing data further demonstrates
that RBM8a regulates multiple processes during brain
development. Functionally, we were also able to deter-
mine what biological functions are significantly mediated
by the RNAs regulated by RBM8a. Interestingly, these
functional categories include neuronal differentiation,
cell proliferation, biological adhesion, and cell migration,
which is consistent with our in vivo data. Also of note, is
that there is a significant number of RNAs in our dataset
that regulate skeletal development and vascular develop-
ment. This is particularly interesting, since TAR syn-
drome, which is caused by a compound mutation in
RBM8a, is characterized by missing radii bones (skeletal
development) and low blood platelet counts (vascula-
ture). Additional enriched functions seem to surround
developmental and neurological processes (Additional
file 7: Table S3).
Since RBM8a play a key role in NMD, we identified
that 814 out of 1788 differentially expressed RNAs pos-
sessed characteristics that would make the RNA prone
to degradation via NMD (long 3′UTR, intron in the 3′
UTR or exon junction > 50 nt downstream of a stop
codon). Functions mediated by these genes include many
developmental processes such as neurogenesis, cell mo-
tility and communication, and the development of the
nervous system (Fig. 9). This data is consistent with thephenotypes seen in our in vitro and in vivo experiments
for knockdown and overexpression of RBM8a. Another
interesting function regulated by these genes is renal
development, which is disrupted in patients with TAR
syndrome [71].
Interestingly, ASD- and SCZ-risk genes are highly rep-
resentative in RBM8a-mediated transcripts. After further
analyzing these differentially expressed RNAs targeted
by NMD by cross-referencing them with risk genes for
neurological disease, ASD, SCZ, AD, and ID risk genes
but not our control, Crohn’s disease were highly repre-
sented in our sample (Additional file 12: Table S7). ASD
risk genes were the most enriched (p = 4.12 × 10−9).
These overlapping genes were found to regulate pro-
cesses associated with neurogenesis, cell communication
and synapse organization, among other functions.
We also used our RNAseq data to assess the effect of
RBM8a overexpression on alternative splicing, seeing
how NMD proteins have been previously determined to
regulate alternative splicing [82]. There were 314 alter-
native splicing events found in our dataset, spanning a
variety of types of alternative splicing. The most promin-
ent type of alternative splicing was skipped exon
(61.4 %), followed by alternative last exon (18.5 %).
9.24 % of alternative splicing events were alternative 5′
splicing site, while 11.15 % were alternative 3′ splicing
site. This data indicates that RBM8a does seem to have
an effect on alternative splicing even though the effect is
small. The genes that were determined to be alterna-
tively spliced were enriched for ASD risk genes, but not
SCZ, AD, ID, or Crohn’s disease risk genes (Additional
file 9: Table S5). This data supports the hypothesis that
RBM8a may be involved in the pathogenesis of ASD
through an increase in alternative splicing of ASD risk
genes.
Throughout all of our analyses of our RNAseq data,
developmental processes, specifically neurogenesis, have
remained consistent among all of our datasets (differen-
tially expressed RNAs, cross-reference with ASD, NMD
targets, alternatively spliced genes etc.). These processes
were those found to be abnormal in our overexpression
and knockdown experiments, indicating an important
role for RBM8a in neural development, and the risk for
neurological and psychiatric disease.
Studies of RBM8a and other NMD factors in embry-
onic brain development may help understand the patho-
physiology of several neurodevelopmental disorders such
as ID, ASD and SCZ. Upf3b gene has been implicated in
ID, ASD and SCZ. In the past several decades, tremen-
dous advancement was made in identification of genetic
components causing ID, ASD, and SCZ. Chromosomal
abnormalities such as copy number variations (CNVs)
including both duplications and deletions are enriched
in many patients with ID, ASD and SCZ [4]. Some of
Zou et al. Neural Development  (2015) 10:18 Page 12 of 16these CNVs, including 1q21 [6], are significantly associ-
ated with all three disorders. As RBM8a is localized in
1q21 region, our studies provide an insight on causes of
mental illnesses and will facilitate the development of
new targets for neurodevelopmental illnesses.
Conclusion
Taken together, our data demonstrate a critical role of
RBM8a in regulation of early neurodevelopment. RBM8a
stimulates embryonic neural progenitor proliferation and
suppresses neuronal differentiation. Unbiased RNA-seq
analysis reveals that RBM8a regulates many risk genes
involved in neurodegenerative/neuropsychiatric diseases
and multiple important functional processes that are im-
portant for early neurodevelopment. Our studies provide
a deeper insight on causes of neurological illnesses.
Methods
Mice
Wild type male and female C57/B6N mice were ob-
tained from Taconic. C57BL/6 N male mice were housed
(2–4 mice per cage) in a room with a light/dark cycle at
12 h interval (lights on at 7:00 am), and provided ad libi-
tum access to food and water. All procedures on mice
were reviewed and approved by The Pennsylvania State
University IACUC committee, under IACUC protocol,
44057, to Yingwei Mao.
Cell culture
Mouse CAD and human 293 T, SH-SY5Y cells were
cultured in DMEM medium containing 10 % FBS, L-
glutamine, and penicillin/streptomycin. Primary NPCs
were isolated from E14 mouse embryos and cultured as
described previously [83]. The cortex from 6 to 8 mouse
brains at E14 were dissected out and trypsinized in 0.5 %
trypsin and DNase at 37 °C for no more than 5 min.
0.2 mg/ml trypsin inhibitor was added to stop the trypsi-
nization and tissues were shattered into single cells by
pipetting. After removal of trypsin solution, cells were
seeded in fibronectin coated plates with NPC medium
(DMEM F-12/1 % Penn-Strep/1 % L-glutamine/1 % N-
2 supplement/bFGF (10–20 ng/ml)). To induce NPC
differentiation, FGF2 was removed from the culture
medium and 1 μM retinoic acid/1 % FBS was added to
the medium for 7 days.
DNA construct, Transfection and Lentivirus production
Human RBM8a cDNA was PCR amplified and cloned
into the lentiviral vector pLV-3FLAG3HA-T2A-GFP as
previously described [53] and pTRIPZ-mCherry to generate
the fusion gene, pTRIPZ-mCherry-RBM8a. The sequences
for shRNAs targeting mouse RBM8a are as follows: control
shRNA: 5′-CGGCTGAAACAAGAGTT GG-3′; shRNA-1:
5′- GCGGACCTTGTGT TTATATTT-3′; shRNA-2:5′- CCATGACAAATTCG CTGAATA -3′; in lentiviral
pLKO.1 vector (Sigma).
Transfection was performed according to a published
protocol using polyethylenimine [84]. Mouse CAD cells
were plated in a 24-well plate on coverslips. Control or
RBM8a shRNAs (0.5 μg) were cotransfected with a GFP
reporter (0.1 μg). To determine the knockdown effect of
RBM8a, cells were fixed in 4 % paraformaldehyde 48 h
posttransfection and stained with RBM8a antibody.
To generate stable SH-SY5Y cell line, pTRIPZ-mCherry
or pTRIPZ-mCherry-RBM8a were cotransfected with
psPAX2, pCMV-VSVG, into 293 T cells using PEI
method. VSVG-pseudotyped lentiviruses were col-
lected 48 after transfection and concentrated by ultra-
centrifugation at 36,000 rpm for 90 min [85]. The
lentiviruses expressing pTRIPZ-mCherry or pTRIPZ-
mCherry-RBM8a were co-infected with virus express-
ing rtTA in SH-SY5Y cells at multiplicity of infection
(MOI) =20. Stable clones were selected by puromycin
selection.
Antibodies and immunoblot
The primary antibodies used in this study were the
following: rabbit anti-HA antibody, mouse anti-F-actin
antibody, mouse anti-RBM8a antibody, goat anti-Sox2
antibody, goat anti-doublecortin (DCX) antibody,
rabbit anti-TLE4 (Santa Cruz); chick anti-GFP anti-
body (Aveslabs), mouse anti-βIII tubulin antibody
(Tuj1, Covance), rabbit anti-Ki67 antibody (Lab Vision),
mouse anti-BrdU antibody (DAKO), rabbit anti-phospho-
Histone H3 ser10 antibody (Millipore), rabbit anti-mCherry
RFP antibody (GenScript), mouse anti-NLGN1, mouse
anti-ATXN1 (NeuromAb); mouse anti-KIF1A (BD Bio-
science). The secondary antibodies used in this study were
obtained from Invitrogen and Jackson ImmunoResearch.
Immunoblots were performed as described previously
[85]. The total proteins were prepared from NPCs, N2a
cells, embryonic cortex at different ages (E9-18) and
adult brain (2 months) using 500 μl cell lysis buffer. Cell
lysis buffer contains 20 mM Tris–HCl (pH 7.5), 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1 % Triton, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate,
1 mM Na3VO4, 1 μg/ml leupeptin, 2 μg/ml aprotinin,
1 mM PMSF. After homogenization on ice for 10 min,
the supernatant of each sample was collected and
stored in aliquots at −70 °C. For each sample, the pro-
tein concentration was determined by Bradford assay
(Thermo Fisher Scientific Inc.). 20–50 μg of cell lysate
were resolved by 12 % SDS-polyacrylamide gel electro-
phoresis and transferred into PVDF membranes. The
protein blots were blocked with 5 % milk in TBS
(10 mM Tris-HCl,pH 8.0, 150 mM NaCl) overnight at
4 °C and incubated with anti-RBM8a antibody, anti-
RFP antibody, anti-Tuj1 antibody, anti-Sox2 antibody,
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2000 in 5 % milk prepared in TBS. The secondary anti-
body was anti-mouse IgG or anti-rabbit IgG (Santa Cruz).
Immunoreactivity was detected with an enhanced chemilu-
minescence detection kit according to the company’s in-
structions (ECL, Millipore).
In utero electroporation, BrdU labeling,
Immunohistochemistry
The pregnant female mouse was anesthetized by intra-
peritoneal (i.p.) injection of avertin (800 ul/40 g) and
Buprenorphine (0.05 mg/kg). The anesthetized female
was put on the sterile warm pad at 37 °C and eye oint-
ment was applied to prevent eyes from drying. Control
or RBM8a shRNA constructs together with an enhanced
GFP (EGFP)-expressing plasmid (final concentration,
2 μg/μl; pCAGIG-Venus) at a 2:1 ratio were injected into
the lateral ventricle of the embryonic brains at E13. In
the overexpression experiments, vector or human WT-
RBM8a plasmid was electroporated into E14 embryonic
brains. The electric pulses were delivered through the
brain of the embryos (5 pulses of 30–45 V). After elec-
troporation, embryos were put back to original position.
The mother mice were sutured and returned to animal
facility for recovery. BrdU (100 mg/kg) was i.p. injected
into mice 2 h before sacrifice. Brains at E16 were re-
moved and post-fixed in 4 % paraformaldehyde at 4 °C
for overnight.
Brain sections (10-μm thick) were blocked with 5 %
normal donkey serum in PBS with 0.3 % Triton X-100
for 60 min and were incubated with primary antibodies,
anti-GFP (1:1000), anti-BrdU (1:500), anti-Ki67 (1:500),
anti-pH3 (1:500), or anti-Tuj1 (1:500) antibodies overnight
at room temperature. After the wash step with PBS,
sections were incubated for 1 h at room temperature
with Alexa488 and Alexa560 labeled secondary antibodies
(1:400, Invitrogen). Sections were then stained with TO-
PRO®-3 DNA dye (Invitrogen) and washed with PBS three
times, and mounted with Anti-fade solution. The distribu-
tion of GFP positive cells was determined by dividing the
number of GFP positive cells in each layer by the total
number of GFP-positive cells in the entire section. In the
cell cycle exit experiments, brains were harvested 24 h after
BrdU injection. Brain sections were then co-stained with
anti-GFP, anti-Ki67 and anti-BrdU antibodies. The cell
cycle exit index was qualified by the ratio of GFP+/
BrdU+/Ki67- to total GFP+/BrdU+ cells. Stereological
quantification of stained cells within the neocortex was
carried out as previously described [86].
Image acquisition and statistical analysis
All images were acquired using a Zeiss LSM Pascal
confocal microscope (Carl Zeiss, USA), and slides were
analyzed by Zeiss LSM image browser software (CarlZeiss, USA), Adobe Photoshop and ImageJ v1.37. Statis-
tical analysis was performed using the student t-test. All
bar graphs are plotted as mean ± SEM. In all analyses,
p < 0.05 was considered statistically significant.
RNA-seq analysis
SH-SY5Y cells stably expressing RBM8a or a control vec-
tor were created as described in the previous section,
and the total RNA was purified from the cells using TRI-
zol reagent. To preserve the noncoding RNAs, we used
RiboZero Kit (Invitrogen) to remove the ribosomal RNA
and RNAs were used for construction of a sequencing li-
brary using the Illumina TruSeq Stranded total RNA Kit
(NIH NHLBI Sequencing Core). One lane of 50 × 50
paired-end reads were generated by the Illumina HiSeq
2500 platform at the NHLBI DNA Sequencing and
Genomics Core (DSGC) and mapped to the human
genome (UCSC build hg19) using Tophat [87]. Gene
type information for each gene was obtained from
GRCh37.75 annotation [88].
Cuffdiff (http://cufflinks.cbcb.umd.edu/) was used with
the reference genomes to identify the differentially
expressed genes and isoforms [87]. The fold change for
each gene was determined by dividing the FPKM for
each gene in the overexpression sample, by the FPKM of
the control sample. The cutoff of genes considered to be
differentially expressed was a q-value of 0.05 or less, and
either greater than a 1.5 fold upregulation or less than a
0.67 fold downregulation.
The list of differentially expressed genes was cross-
referenced with databases consisting of genes known to
be associated with various neurological disease. The
number of genes present in both datasets was deter-
mined, and a hypergeometric analysis was used to iden-
tify the statistical probability that the genes in common
were due to chance (data presented had a p < 0.05).
The list of common genes generated in the cross-
reference with disease databases was then input in to
DAVID gene functional classification tool (functional
annotation cluster). DAVID identified what signaling
pathways and what functional categories were signifi-
cantly affected (Fisher exact test) based on the number
of genes in the pathway located in the dataset.
For the alternative splicing analysis, all bam files cre-
ated by TopHat (version 2.0.6) [89] were merged into a
single files using samtools (version 1.1) [90]. The total
number of reads that support the individual variants as-
sociated with each of the predicted functional alternative
splicing events were determined using the MISO pack-
age (version 0.5.3) [91] using events annotated as of 26
June 2013.
Significant differentially spliced events were deter-
mined by requiring a Bayes’ factor >10 and Δψ >0.2 in a
comparison of cherry and RBM8a. Each event was
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age thresholds.
Transcripts targeted by NMD were determined by
cross-referencing the list of differentially expressed
RNAs with the hg19 annotation. Targets were identified
as targeted by NMD if they had a 3′ UTR greater than
or equal to 1250 bp, an intron in the 3′ UTR, or an exon
junction greater than 50 nt downstream of a stop codon
[74]. All RNAseq data has been submitted to Genbank
(Bioproject PRJNA283786).
Additional files
Additional file 1: Confirmation of RBM8a shRNAs in vitro. a. Control
or RBM8a shRNAs were transfected into CAD cells. 48 h posttransfection,
protein lysates were probed with specific RBM8a mouse monoclonal
antibody. b. Control or RBM8a shRNA2 was cotransfected with a GFP
expressing construct in CAD cells. After 48 h, cells were stained with
RBM8a antibody (red) and GFP (green) to show specific knockdown
of endogenous RBM8a. White arrows indicated that RBM8a shRNA
expressing cells express significantly low level of RBM8a compared to
non-transfected cells (yellow arrowhead) in the same field.
Additional file 2: RBM8a regulates cell proliferation in vitro. a.
Control or RBM8a shRNA2 was cotransfected with a GFP expressing
construct in CAD cells. After 48 h, cells were pulse labeled with 10 μM
BrdU for 30 min and stained with BrdU antibodies. Graphs show the
percentage of GFP/BrdU double positive cells in each condition. ***,
p < 0.001; n = 3. t-test. b. Control or RBM8a shRNA2 was cotransfected
with a GFP expressing construct in CAD cells. After 48 h, cells were fixed
with 4 % paraformaldehyde and stained with pH3 antibodies. Graphs
show the percentage of GFP/ pH3 double positive cells in each
condition. *, p < 0.05; n = 3. t-test. c. Vector or RBM8a overexpression
plasmid was cotransfected with a GFP expressing construct in CAD cells.
After 48 h, cells were pulse labeled with 10 μM BrdU for 30 min and
stained with BrdU antibodies. Graphs show the percentage of GFP/BrdU
double positive cells in each condition. *, p < 0.05; n = 3. t-test. d. Vector
or RBM8a overexpression plasmid was cotransfected with a GFP expressing
construct in CAD cells. After 48 h, cells were fixed with 4 % paraformaldehyde
and stained with pH3 antibodies. Graphs show the percentage of GFP/ pH3
double positive cells in each condition. *, p< 0.05; n= 3. t-test.
Additional file 3: RBM8a regulates cell migration in vivo. a. Confocal
images of E18 brain sections showing cell positioning after in utero
electroporation of shRNA constructs at E15. The graph shows that
knockdown of RBM8a significantly decreased the number of GFP-positive
cells in the VZ/SVZ and increased the cell number in the CP. b. E16 brain
sections staining with GFP and Tuj1 (red) show cell positioning after in
utero electroporation of RBM8a shRNAs construct at E13. C. E16 brain
sections staining with GFP and Tuj1 (red) show cell positioning after in
utero electroporation of an overexpression construct at E14.
Additional file 4: RNAseq quality of RBM8a stable RBM8a
overexpression line. a. Stable SH-SY5Y cells stably expressing
mCherry or RBM8a-mCherry gene were confirmed by Western blotting by
anti-mCherry antibody. b. Illumina Hi-Seq per base sequence quality for
SH-SY5Y cells stably expressing mCherry. c. Illumina Hi-Seq per base sequence
quality for SH-SY5Y cells stably expressing RBM8a-mCherry.
Additional file 5: Table S1. Percentage of different types of RNAs.
Additional file 6: Table S2. RBM8a regulates Genes that are involved in
risks of diseases.
Additional file 7: Table S3. Functional Clusters of RBM8a downstream
genes.
Additional file 8: Table S4. List of alternatively spliced protein coding
RNAs.
Additional file 9: Table S5. RBM8a mediated alternative splicing genes
significantly overlap with ASD risk genes.Additional file 10: Table S6. Differentially expressed RNAs that are
potential NMD targets.
Additional file 11: Functional clusters of overlapping genes from
potential RBM8a mediated NMD targets and ASD risks. a. Number
of genes that overlaps between potential NMD targets and ASD risk.
b. Functional clusters of the overlapping genes.
Additional file 12: Table S7. RBM8a mediated potential NMD targets
significantly overlap with risk genes for neurological disease.
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